Population Pharmacokinetic Analysis to Support and Facilitate Switching from Risperidone Formulations to Rykindo in Patients with Schizophrenia

Population Pharmacokinetic Analysis to Support and Facilitate Switching from Risperidone Formulations to Rykindo in Patients with Schizophrenia

Abstract Introduction RYKINDO® (Rykindo) is a novel, long-acting injectable risperidone formulation administered biweekly (Q2W) through intramuscular gluteal injection for the treatment of schizophrenia in adult patients. This analysis was conducted to demonstrate that the clinical outcomes of Rykin...

Full description

Bibliographic Details
Main Authors: Wenyan Wang, Xiaofeng Wang, Ying Dong, David P. Walling, Pinglan Liu, Wanhui Liu, Yanan Shi, Kaoxiang Sun
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-01-01
Series:Neurology and Therapy
Subjects:
Risperidone
Long-acting injection
Population pharmacokinetic model
Switching from Consta to Rykindo
Dosing window
Online Access:https://doi.org/10.1007/s40120-024-00578-w

Internet

https://doi.org/10.1007/s40120-024-00578-w

Similar Items